News
Combined therapy makes headway for liver cancer
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center.
Cancer cell–immune cell interactions predict immunotherapy response
By examining which genes were turned on and off in a mix of cell types from breast cancer biopsies, a team led by UT Southwestern Medical Center researchers developed a tool that can accurately predict which patients with breast cancer will respond to immunotherapies.
Blocking gene may halt growth of breast cancer cells
Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive (ER+) breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical Center researchers showed in a new study.
Drug targeting clear cell renal cell carcinoma shows promising approach
– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).
Recruitment underway at O’Donnell School of Public Health to meet industry growth and demand
O'Donnell School of Public Health recruits for the 2024-2025 school year.